Aripiprazole Tablet
Product Images NDC 71335-1364

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1364). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (Aripiprazole Fig1)

A pharmacokinetic chart showing the effects of various drugs on aripiprazole, depicting fold changes in AUC and Cmax with 90% confidence intervals relative to a reference without interacting drugs. The drugs include CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lorazepam). The horizontal axis represents change relative to reference, ranging approximately from 0.0 to 3.0.*

FDA Label Image

Figure 2: The Effects Of Other Drugs On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig2)

A scatter plot figure depicting the effects of various drugs on the pharmacokinetics of dehydro-aripiprazole. The x-axis shows the fold change relative to a reference without the interacting drug (ranging from 0 to 3), and the y-axis lists drugs that are CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others. Data points include ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam, showing changes in AUC and Cmax with 90% confidence intervals.*

FDA Label Image

Figure3: The Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig3)

A chart titled 'The effects of aripiprazole on pharmacokinetics of other drugs,' illustrating fold changes and 90% confidence intervals for various drugs' pharmacokinetic parameters relative to reference values without interacting drugs. It compares parameters like AUC, Cmax, and INR across multiple drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lorazepam, and venlafaxine.*

FDA Label Image

Figure4: Effects Of Intrinsic Factors On Aripiprazole Pharmacokinetics (Aripiprazole Fig4)

A forest plot chart titled 'Aripiprazole Fold Change and 90% CI' showing the fold changes in pharmacokinetic parameters (AUC and Cmax) compared to reference values across different special populations. These populations include CYP2D6 metabolizer status, gender, age groups, degrees of hepatic impairment, and severe renal impairment. The x-axis represents fold change relative to the reference, ranging from 0.5 to 3.0, with error bars indicating 90% confidence intervals.*

FDA Label Image

Figure 5: Effects Of Intrinsic Factors On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig5)

A forest plot chart showing the effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics, specifically fold changes and 90% confidence intervals for AUC and Cmax. Factors compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with changes relative to reference plotted along the x-axis.*

FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

A Kaplan-Meier curve showing the cumulative proportion of patients with relapse over days from randomization in a schizophrenia study. The graph compares two groups: Aripiprazole and placebo, with Aripiprazole group showing a lower proportion of relapse over time. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The number of subjects at risk is indicated below the x-axis for each time point.*

FDA Label Image

Aripiprazole Fig7

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares Aripiprazole at low and high doses and a placebo, with the Y-axis representing least-squares mean change in score and the X-axis representing weeks of treatment. Both Aripiprazole doses show a greater reduction in tic scores over time compared to placebo.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, showing the molecular components including a dichlorophenyl group, piperazine ring, and a quinolinone moiety linked by an ethoxypropyl chain.*

FDA Label Image

Label Image (Lbl713351364)

Aripiprazole 20 mg tablet packaging label by Bryant Ranch Prepack. The label indicates comparison to Abilify 20 mg tablet by Aurobindo Pharma USA. It includes storage instructions at 20°-25°C (68°-77°F), a warning to keep out of reach of children, the package count of 30 tablets, and the product NDC 71335-13641.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.